3-溴-1-甲基-1H-吡咯[2,3-B]吡啶 | 281192-91-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 3-溴-1-甲基-1H-吡咯[2,3-B]吡啶
• 中文别名: 3-溴-1-甲基-7-氮杂吲哚
• 英文名称: 3-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 3-bromo-1-methylpyrrolo[2,3-b]pyridine
• CAS: 281192-91-4
• 化学式: C₈H₇BrN₂
• 分子量: 211.061
• InChiKey: GBHFSEKDEABVOP-UHFFFAOYSA-N

物化性质

• 沸点：
  315.3±22.0 °C(Predicted)
• 密度：
  1.505 g/mL at 25 °C
• 闪点：
  >110℃

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromo-1-methylpyrrolo[2,3-b]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-1-methylpyrrolo[2,3-b]pyridine
CAS number: 281192-91-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H7BrN2
Molecular weight: 211.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-1-甲基-1H-吡咯[2,3-B]吡啶 生成 ((1s,3s)-3-Hydroxy-3-methylcyclobutyl)(7-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-azaspiro[3.5]nonan-2-yl)methanone
  参考文献：
  名称：

  CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS

  摘要：

  式(I)的化合物及其药用盐、同位素、N-氧化物、溶剂合物和立体异构体，包含它们的药物组合物，制备它们的方法以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、疾病和症状的方法，如与疼痛、精神障碍、神经障碍（包括但不限于抑郁症、重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合征和躁狂症）、癌症和眼部疾病相关的疾病状态、疾病和症状：其中R1、R3和L如本文所定义。

  公开号：

  US20220089538A1
• 作为产物：
  描述：

  1-甲基-7-氮杂吲哚 在 溴 作用下， 以 二氯甲烷 为溶剂， 反应 13.0h， 以94%的产率得到3-溴-1-甲基-1H-吡咯[2,3-B]吡啶
  参考文献：
  名称：

  A Facile Synthesis of 1-Alkyl-7-azaisatins

  摘要：

  1-alkyl-7-azaisatins are synthesized from the reaction of 1-alkyl-7-azaindoles with bromine in dichloromethane and subsequent oxidation with N-bromosuccinimide - dimethyl sulfoxide reagent. 1-Alkyl-7-azaindoles are readily available in high yields from the reaction of sodium salt of 7-azaindole with the appropriate alkyl halides in dimethylacetamide.

  DOI：

  10.3987/com-99-8792

文献信息

• [EN] ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINE ARYL-BIPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL PHOSPHATE KINASE
  申请人：PETRA PHARMA CORP

  公开号：WO2019126733A1

  公开（公告）日：2019-06-27

  The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I): wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.

  这项发明涉及PI5P4K抑制剂，用于治疗癌症、神经退行性疾病、炎症性疾病和代谢性疾病，其化学式为（I）：其中A、X、Y、Z、Q、R1、R2、R3、R4、R5和n如本文所述。
• C−H Cyanation of 6-Ring N-Containing Heteroaromatics
  作者：Bryony L. Elbert、Alistair J. M. Farley、Timothy W. Gorman、Tarn C. Johnson、Christophe Genicot、Bénédicte Lallemand、Patrick Pasau、Jakub Flasz、José L. Castro、Malcolm MacCoss、Robert S. Paton、Christopher J. Schofield、Martin D. Smith、Michael C. Willis、Darren J. Dixon

  DOI：10.1002/chem.201703931

  日期：2017.10.20

  them have the potential for far‐reaching impact across synthetic chemistry and the biomedical sciences. Herein, we report an approach to heteroaromatic C−H cyanation through triflic anhydride activation, nucleophilic addition of cyanide, followed by elimination of trifluoromethanesulfinate to regenerate the cyanated heteroaromatic ring. This one‐pot protocol is simple to perform, is applicable to a broad

  杂芳腈是药物发现中的重要化合物，因为它们在临床上很普遍，而且因为它们可以经历各种各样的转化。因此，有效且可靠的获取它们的方法有可能对合成化学和生物医学产生深远的影响。在此，我们报告了一种通过三氟甲磺酸酐活化、氰化物亲核加成、然后消除三氟甲亚磺酸盐以再生氰化杂芳环来进行杂芳族CH氰化的方法。这种一锅法操作简单，适用于多种修饰的6环含氮杂环化合物，并且已被证明适用于复杂类药物结构的后期功能化。
• Generation of Aryl and Heteroaryl Magnesium Reagents in Toluene by Br/Mg or Cl/Mg Exchange
  作者：Dorothée S. Ziegler、Konstantin Karaghiosoff、Paul Knochel

  DOI：10.1002/anie.201802123

  日期：2018.5.28

  very fast Br/Mg exchange with aryl and heteroaryl bromides, producing aryl and heteroaryl magnesium alkoxides (ArMgOR⋅LiOR) in toluene. These Grignard reagents react with a broad range of electrophiles, including aldehydes, ketones, allyl bromides, acyl chlorides, epoxides, and aziridines, in good yields. Remarkably, the related reagent sBu2Mg⋅2 LiOR (R=2‐ethylhexyl) undergoes Cl/Mg exchange with various

  以1.5 m的甲苯溶液形式制备的烷基镁醇盐sBuMgOR·LiOR（R = 2-乙基己基）， 与芳基和杂芳基溴化物进行非常快速的Br / Mg交换，从而生成芳基和杂芳基镁醇盐（ArMgOR·LiOR）。甲苯。这些格氏试剂与多种亲电子试剂反应，收率很高，包括醛，酮，烯丙基溴，酰氯，环氧化物和氮丙啶。值得注意的是，相关的试剂SBU 2 Mg⋅2LIOR（R = 2-乙基己基）经历CL /在甲苯各种富电子芳基氯化物的Mg交换，产生类型的Ar diorganomagnesium物种2 Mg⋅2LIOR，其与醛反应良好和烯丙基溴。
• In-Situ Bromination Enables Formal Cross-Electrophile Coupling of Alcohols with Aryl and Alkenyl Halides
  作者：Benjamin K. Chi、Jonas K. Widness、Michael M. Gilbert、Daniel C. Salgueiro、Kevin J. Garcia、Daniel J. Weix

  DOI：10.1021/acscatal.1c05208

  日期：2022.1.7

  coupling are limited. We report the use of 1° and 2° alcohols in cross-electrophile coupling with aryl and vinyl halides to form C(sp3)–C(sp2) bonds in a one-pot strategy utilizing a very fast (<1 min) bromination. The reaction’s simple benchtop setup and broad scope (42 examples, 56% ± 15% average yield) facilitates use at all scales. The potential in parallel synthesis applications was demonstrated by successfully

  尽管醇是最大的烷基底物库之一，但在交叉偶联和交叉亲电子偶联中利用它们的方法是有限的。我们报道了使用 1° 和 2° 醇与芳基和乙烯基卤化物进行交叉亲电子偶联，利用非常快的 (<1 min) 的一锅策略形成 C(sp 3 )–C(sp 2 ) 键溴化。该反应简单的台式设置和广泛的范围（42 个示例，平均产率 56% ± 15%）便于在所有规模上使用。通过在 96 孔板中成功偶联 8 种醇与 12 个芳基核心的所有组合，证明了并行合成应用的潜力。
• Pyrrolopyrazine kinase inhibitors
  申请人：Roche Palo Alto

  公开号：US07939531B2

  公开（公告）日：2011-05-10

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式I中的新型吡咯吡嗪衍生物，其中变量Q和R的定义如本文所述，该衍生物抑制JAK和SYK，并且适用于治疗自身免疫和炎症性疾病。